Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) CEO Acquires $534,500.00 in Stock

Posted by Alanna Baker on Feb 8th, 2025

MBX Biosciences, Inc. (NYSE:MBX – Get Free Report) CEO P. Kent Hawryluk bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were acquired at an average price of $10.69 per share, with a total value of $534,500.00. Following the acquisition, the chief executive officer now owns 448,277 shares of the company’s stock, valued at $4,792,081.13. This represents a 12.55 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

MBX Biosciences Stock Up 0.7 %

Shares of MBX Biosciences stock opened at $12.34 on Friday. The company’s 50 day simple moving average is $16.10. MBX Biosciences, Inc. has a 52 week low of $9.42 and a 52 week high of $27.50.

MBX Biosciences (NYSE:MBX – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($2.78) EPS for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.06). On average, equities analysts predict that MBX Biosciences, Inc. will post -13.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MBX Biosciences

A number of institutional investors have recently added to or reduced their stakes in MBX. Rhumbline Advisers bought a new position in MBX Biosciences in the fourth quarter worth $175,000. Point72 Asia Singapore Pte. Ltd. bought a new position in MBX Biosciences in the third quarter worth $278,000. Point72 Asset Management L.P. bought a new position in MBX Biosciences in the third quarter worth $405,000. Barclays PLC bought a new position in MBX Biosciences in the third quarter worth $426,000. Finally, Bank of New York Mellon Corp bought a new position in MBX Biosciences in the fourth quarter worth $441,000.

About MBX Biosciences

(Get Free Report)

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.